Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

ated in order to integrate the virus in the panoply of agents used for sarcoma treatment."

"These results are consistent with what we observed on an interim basis when we reported data on the first 16 patients back in June 2008," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is encouraging that we are observing stable disease in a range of sarcomas and the clinical benefit is not isolated to any specific type."

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the CTOS meeting with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actua
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... SAN DIEGO , Feb. 16 BioMed Realty ... of an amendment to its lease with Ironwood Pharmaceuticals, Inc. (Nasdaq: ... in Cambridge, Massachusetts .  Ironwood has agreed to lease an ... its existing premises located in the heart of the Kendall Square ...
... , SAN FRANCISCO , Feb. 16 ... showcase innovative new initiatives at Informex this week, highlighting the ... to the global chemicals industry. , At Informex 2010, ... between seven leading universities, the private sector and the Scottish ...
... PLEASANTON, Calif. , Feb. 16 ... proprietary chemistry for nucleic acid testing applications that are relevant ... for the "Most Promising Company" award at the Personalized Medicine ... The PMWC 2010 was created to examine the emerging field ...
Cached Biology Technology:BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 2BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 3BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 4Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 2Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 3Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 4QuantaLife, Inc. Unanimously Selected as the 'Most Promising Company' at the Personalized Medicine World Conference 2010 2QuantaLife, Inc. Unanimously Selected as the 'Most Promising Company' at the Personalized Medicine World Conference 2010 3QuantaLife, Inc. Unanimously Selected as the 'Most Promising Company' at the Personalized Medicine World Conference 2010 4
(Date:4/15/2014)... pairs, researchers from the Bloomberg School of Public ... reuptake inhibitors (SSRIs), a frequently prescribed treatment for ... autism spectrum disorder (ASD) and developmental delays (DD) ... edition of Pediatrics , analyzed data from ... population-based controls, where a uniform protocol was implemented ...
(Date:4/15/2014)... who study the deadliest infectious diseases recognized the contributions ... at the University of Texas Medical Branch, with a ... on Filoviruses. The filoviruses include Ebola and Marburg viruses ... people infected. The current outbreak of Ebola virus raging ... so far. , "This award represents the culmination ...
(Date:4/15/2014)... form could help reduce side effects by targeting the ... have developed nanoparticles that deliver one or two chemotherapy ... particles that can carry any more than that in ... a new way to build such nanoparticles, making it ... In a paper published in the Journal of ...
Breaking Biology News(10 mins):Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3
... held its breath when the tanker Jessica, loaded with 150,000 ... in the heart of one of the most precious, famous ... At risk were vast numbers of unique species of flora ... to his landmark theory of evolution by natural selection. ...
... policy-makers, business leaders and environmentalists are joining forces to ... taking part in an influential new forum at the ... February 22, the Nitrous Oxide Focus Group will engage ... Marks & Spencer, British Sugar, Defra, the Country Land ...
... , Imagine a gigantic, inflatable, sausage-like bag capable of ... equivalent of 2.2 days of current global emissions. Now try ... radius and several kilometres long, resting benignly on the seabed ... first blush, this might appear like science fiction, but its ...
Cached Biology News:First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4Nitrous oxide: definitely no laughing matter 2Into the abyss: Deep-sixing carbon 2
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: